よくわかるシリーズ　透析療法必須知識

出版社： 東京医学社
著者：
発行日： 2017-06-20
分野： 臨床医学：内科  >  腎臓
ISBN： 9784885632853
電子書籍版： 2017-06-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,970 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,970 円(税込)

購入する

目次

  • よくわかるシリーズ　透析療法必須知識

    ―目次―

    急性腎障害（AKI）の診断・治療
    on-line HDFの実際
    心血管合併症
    アフェレシスの実際
    バスキュラーアクセス〜原理，作製，管理まで〜
    バスキュラーアクセス合併症
    腹膜透析（PD）関連手術
    透析患者の薬物療法up to date
    慢性創傷の治療
    透析患者の脳萎縮と認知機能障害
    透析患者の貧血と鉄補充療法
    CKD-MBD治療（薬物療法）
    VAIVT（Vascular Access Intervention Therapy）
    PD-HD併用（ハイブリット）療法
    穿刺技術の実際
    透析関連液の生物学的汚染の測定
    最新C型肝炎治療を透析患者にどう適応する？
    わかりやすい脆弱性骨折対策
    透析患者に対する運動療法
    カーボカウントによる糖尿病透析患者の食事指導

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

急性腎障害 ( AKI ) の診断・治療

P.10 掲載の参考文献
1. Bellomo R, et al : Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs : the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 : R204-212, 2004
PubMed
2. Mehta RL, et al : Acute Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury. Crit Care 11 : R31, 2007
PubMed
3. KDIGO Clinical Practice Guideline for Acute Kidney Injury : Kidney Int (Suppl 2) : 1-138, 2012
 
4. Levey AS, et al : Definition and classification of kidney diseases. Am J Kidney Dis 61 : 686-688, 2013
PubMed
5. Wald R, et al : Changing incidence and outcomes following dialysis-requiring acute kidney injury among critically ill adults : a population-based cohort study. Am J Kidney Dis 65 : 870-877, 2015
PubMed
6. Hsu CN, et al : Incidence, Outcomes, and Risk Factors of Community-Acquired and Hospital Acquired Acute Kidney Injury : A Retrospective Cohort Study. Medicine (Baltimore) 95 : e3674, 2016
PubMed
7. Harel Z,et al : Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int 83 : 901-908, 2013
PubMed
8. Hoste EA, et al : RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients : a cohort analysis. Crit Care10 : R73, 2006
 
9. Cerda J et al : Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 3 : 881-886, 2008
PubMed
10. Chawla LS, et al : Acute kidney injury and chronic kidney disease : an integrated clinical syndrome. Kidney Int 82 : 516-524, 2012
PubMed
11. Thakar CV, et al : Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 6 : 2567-2572, 2011
PubMed
12. Barry M, et a (l ed) : Brenner & Rector's The Kidney. 5 th (ed), WB Saunders, Philadelphia, 1996
 
13. 柴垣有吾 : より理解を深める! 体液電解質異常と輸液. 中外医学社, 東京, 2007
 
14. Scolari F, et al : Cholesterol crystal embolism : A recognizable cause of renal disease. Am J Kidney Dis 36 : 1089-1109, 2000
PubMed
15. 宮地武彦, 他 : 抗悪性腫瘍による腎障害. Nephrol Fronti 3 : 108-111, 2004
 
16. Himmelfarb J, et al : Acute kidney injury : changing lexicography, definitions, and epidemiology. Kidney Int 71 : 971-976, 2007
PubMed
17. Lameire N, et al : The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2 : 364-377, 2006
PubMed
18. Doi K, et al : Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Critical Care Med 39 : 2464-2469, 2011
 
19. Singri N, et al : Acute renal failure. JAMA 289 : 747-751, 2003
PubMed
20. Onuigbo MA : Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients? Nephron Clin Pract118 : 407-419, 2011
 
21. Steven Mc Gee (著), 柴田寿彦, 他 (訳) : マクギー身体診断学 エビデンスにもとづくグローバル・スタンダード. エルゼビア・ジャパン, 東京, 2014
 
22. Praga M, et al : Acute interstitial nephritis. Kidney Int 77 : 956-961, 2010
PubMed
23. Orient JM (著), 須藤博, 他 (翻訳) : サパイラ 身体診察のアートとサイエンス. 第4版, 医学書院, 東京, 2013
 
24. Doi K, et al : Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol 20 : 1217-1221, 2009
PubMed
25. Moran SM, et al : Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 27 : 928-937, 1985
 
26. Chen S : Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely. J Am Soc Nephrol 24 : 877-888, 2013
PubMed
27. Abuelo JG : Normotensive ischemic acute renal failure. N Engl J Med 357 : 797-805, 2007
PubMed
28. Dellinger RP, et al : Surviving Sepsis Campaign : International Guidelines for Management of Severe Sepsis and Septic Shock : 2012. Crit Care Med 41 : 580-637, 2013
PubMed
29. National Heart, et al : Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354 : 2564-2575, 2006
PubMed
30. Mullens W, et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
31. Ding X, et al : Intravenous Fluids and Acute Kidney Injury. Blood Purif 43 : 163-172, 2017
PubMed

on - line HDFの実際

P.17 掲載の参考文献
1. 日本透析医学会 : 図説 わが国の慢性透析患者の現況. (2015年12月31日現在)
 
2. 秋葉隆, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-167, 2008
 
3. Kawanishi H, et al : Standard on Microbiological Management of Fluids for Hemodialysis and Related Therapies by the Japanese Society for Dialysis Therapy 2008. Ther Apher Dial 13 (2) : 161-166, 2009
PubMed
4. Masakane I, et al : 2011 JSDT standard on the management of endotoxin retentive filter for dialysis and related therapies. Ther Apher Dial 17 (2) : 229-240, 2013
PubMed
5. 日本透析医学会 : 図説 わが国の慢性透析患者の現況. (2013年12月31日現在)
 
6. Grooteman MP, et al : Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 23 : 1087-1096, 2012
PubMed
7. Penne EL, et al : Results from the RISCAVID study : is haemodiafiltration associated with improved survival? Nephrol Dial Transplant 23 (9) : 3034 ; author reply 3035, 2008
 
8. Ok E, et al : Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis : results from the Turkish OL-HDF Study. Nephrol Dial Transplant 28 (1) :192-202, 2013
PubMed
9. Maduell F, et al : High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24 (3) : 487-497, 2013
PubMed

心血管合併症

P.24 掲載の参考文献
1. 政金生人, 他 : わが国の慢性透析療法の現況 (2015年12月31日現在). 日透析医会誌 50 : 1-62, 2017
 
2. 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 (5) : 337-425, 2011
 
3. Ohtake T, et al : High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy : an angiographic examination. J Am Soc Nephrol 16 : 1141-1148, 2005
PubMed
4. Shroff GR, et al : Trends in Mortality Following Acute Myocardial Infarction Among Dialysis Patients in the United States Over 15 Years. J Am Heart Assoc 4 : e002460, 2015
PubMed
5. Nishimura M, et al : Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 66 : 811-819, 2004
PubMed
6. Nishimura M, et al : Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol 51 : 139-145, 2008
PubMed
7. NSFとガドリニウム造影剤使用に関する合同委員会 (日本医学放射線学会・日本腎臓学会) : 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン (第2版 : 2009年9月2日改訂). 日腎会誌 51 : 839-842, 2009
 
8. Apple FS, et al : Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106 : 2941-2945, 2002
 
9. Martin GS, et al : Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant 14 : 1030-1031, 1999
 
10. Green TR, et al : Diagnostic value of creatine kinase and creatine kinase MB isoenzyme in chronic hemodialysis patients : a longitudinal study. Clin Nephrol 25 : 22-27, 1986
PubMed
11. ISLSコースガイドブック編集委員会 (編), 日本救急医学会, 日本神経救急医学会 (監) : ISLSコースガイドブック-脳卒中初期診療のために. へるす出版, 東京, 2006
 
12. 日本脳卒中学会, 脳卒中ガイドライン委員会 (編) : 脳卒中治療ガイドライン 2015. 協和企画, 東京, 2015
 

アフェレシスの実際

P.32 掲載の参考文献
1. 江口圭 : 置換液の使用方法と至適濃度設定法. 日アフェレシス会誌 26 : 36-47, 2007
 
2. 中園和子 : アフェレシスデバイス使用マニュアル (簡易版) 2011. 日アフェレシス会誌 30 (3) : 369-387, 2011
 

バスキュラーアクセス ～原理, 作製, 管理まで～

P.37 掲載の参考文献
1. 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現状 (2015年12月31日現在). http://docs.jsdt.or.jp/overview/ (2017.4.25アクセス)
 
2. 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 (9) : 1491-1551, 2005
 

バスキュラーアクセス合併症

P.43 掲載の参考文献
1. 日本透析医学会 : 2011年版 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 44 (9) : 855-937, 2011
 

腹膜透析 ( PD ) 関連手術

P.51 掲載の参考文献
1. Twardowski ZJ, et al : Swan neck presternal ("bath tub") catheter for peritoneal dialysis. Adv Perit Dial 8 : 316-324, 1992
PubMed
2. 窪田実, 他 : バスタブカテーテル (presternal catheter) の成績. 腎と透析 49 : 59-63, 2000
 
3. 窪田実, 他 : 上腹部カテ-テル出口 (Upper abdominal exit ; UAE) はさまざまな利点を有する. 腎と透析 61 別冊腹膜透析 2006 : 393-394, 2006
 
4. 窪田実 : 背中の肩甲骨部にPDカテーテル出口 (Shoulder Blade Exit ; SBE) を作製した. 腎と透析 65 別冊アクセス 2008 : 149-150, 2008
 
5. 岡本貴行, 他 : 腹膜透析カテーテルの腹腔内挿入にスタイレットは必要ない-ノンスタイレット挿入法-. 透析会誌 43 : 569-573, 2010
 
6. 窪田実, 他 : 腹膜透析の新しい導入法 ; "Moncrief and Popovichのカテーテル挿入法" を用いた段階的導入. 透析会誌 35 : 1279-1285, 2002
 
7. Kubota M : Implantation of presternal catheter using Moncrief technique : aiming for fewer catheter-related complication. PDI 21 (Suppl) : S205-208, 2001
 
8. 窪田実, 他 : PDカテーテル閉塞に対するCRF (Catheter Repair by the forefinger). 透析会誌 43 (Suppl 1) : 603, 2010
 

透析患者の薬物療法 up to date

P.59 掲載の参考文献
1. 成末まさみ, 他 : プレガバリンは腎機能を考慮した推奨用量でも腎機能低下患者の有害事象発生率が高い. 透析会誌 48 : 155-161, 2015
 
2. Palmer SC, et al : Phosphate-binding agents in adults with CKD: A network meta-analysis of randomized trials. Am J Kidney Dis 68 : 691-702, 2016
PubMed
3. Covic A, et al : Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol 14 : 153, 2013
PubMed
4. Schmid H, et al : Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis : a critical review of the literature. Eur J Med Res 14 : 185-190, 2009
PubMed
5. Nerbass FB, et al : Adherence and knowledge about hyperphosphatemia treatment in hemodialysis patients with hyperphosphatemia. J Bras Nefrol 32 : 149-155, 2010
PubMed
6. Ahlenstiel T, et al : Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant 25 : 3241-3249, 2010
PubMed
7. Nolan CR, et al : Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J 87 : 894-898, 1994
PubMed
8. Gupta A : Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel) 7 : 990-998, 2014
PubMed
9. Fong T, et al : Pregabalin-associated heart failure decompensation in a patient with a history of stage I heart failure. Ann Pharmacother 48 : 1077-1081, 2014
 
10. Cabrera J, et al : Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 28 : 1027-1037, 2012
PubMed
11. Irving G, et al : Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Int J Clin Pract 68 : 1130-1140, 2014
PubMed
12. Tsai WC, et al : Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res 29 : 67-73, 2011
PubMed
13. Chang HN, et al : The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin. J Orthop Res 30 : 764-768, 2012
PubMed
14. Menon A, et al: New insights in extracellular matrix remodeling and collagen turnover related pathways in cultured human tenocytes after ciprofloxacin administration. Muscles Ligaments Tendons J 3 : 122-131, 2013
PubMed
15. Tsai WC, et al : Fluoroquinolone-associated tendinopathy. Chang Gung Med J 34 : 461-467, 2011
PubMed
16. Lewis T, et al : Fluoroquinolones and tendinopathy : a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 49 : 422-427, 2014
 

慢性創傷の治療

P.69 掲載の参考文献
1. 寺師浩人: 糖尿病足病変の病態. 市岡滋, 他 (編) : 足の創傷をいかに治すか-糖尿病 フットケア・Limb Salvageへのチーム医療-, 58-71, 克誠堂出版, 東京, 2009
 
2. Schultz GS, et al : Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 11 (Suppl 1) : S1-28, 2003
 
3. Falanga V : Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 8 : 347-352, 2000
PubMed
4. Leaper DJ, et al : Extending the TIME concept: what have we learned in the past 10 years?. Int Wound J 9 (Suppl 2) : 1-19, 2012
 
5. Wolcott RD, et al : Biofilm-based wound care. Adv Wound Care 1 : 311-316, 2008
 
6. Percival S, et al : Biofilms and their potential role in wound healing. Wounds 16 : 234-240, 2004
 
7. Falanga V, et al : Maintenance debridement in the treatment of difficult-to-heal chronic wounds. Recommendations of an expert panel. Ostomy Wound Manage (Suppl) : 2-13, Quiz 14-15, 2008
 
8. Davis J : Combining wound debridement modalities with negative pressure wound therapy. Abstract #123, WOCN Society 38 th Annual Conference, 2006
 
9. Motomura H, et al : Aggressive conservative therapy for refractory ulcer with diabetes and/or arteriosclerosis. J Dermatol 33 : 353-359, 2006
PubMed
10. 元村尚嗣, 他 : 難治性足病変に対する積極的保存的療法の試み. 創傷 2 : 11-19, 2011
 
11. 元村尚嗣 : 慢性創傷-TIMEコンセプトにのっとった治療-. 日創傷オストミー失禁管理会誌 18 : 279-284, 2014
Medical*Online
12. 元村尚嗣 : 糖尿病足病変の病因と治療. 稲葉雅章 (監修), 絵本正憲, 他 (編) : 糖尿病腎症の治療のポイント-早期腎症から透析療法まで-, 357-364, 医薬ジャーナル社, 大阪, 2016
 

透析患者の脳萎縮と認知機能障害

P.76 掲載の参考文献
1. Yoshimitsu T, et al : Cerebral ischemia as a causative mechanism for rapid progression of brain atrophy in chronic hemodialysis patients. Clin Nephrol 53 : 445-451, 2000
PubMed
2. Taki Y, et al : Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging 25 : 455-463, 2004
PubMed
3. Tsuruya K, et al : Brain atrophy in peritoneal dialysis and CKD stages 3-5 : a cross-sectional and longitudinal study. Am J Kidney Dis 65 : 312-321, 2015
PubMed
4. Tsuruya K, et al : Clinical significance of fronto-temporal gray matter atrophy in executive dysfunction in patients with chronic kidney disease : The VCOHP Study. PLoS One 10 : e0143706, 2015
PubMed
5. Pereira AA, et al : Cognitive function in dialysis patients. Am J Kidney Dis 45 : 448-462, 2005
PubMed
6. Drew DA, et al : Cognitive decline and its risk factors in prevalent hemodialysis patients. Am J Kidney Dis pii : S0272-6386 (16) 30707-7, 2017
 
7. Hirakata H, et al : CBF and oxygen metabolism in hemodialysis patients : effects of anemia correction with recombinant human EPO. Am J Physiol 262 : F737-743, 1992
PubMed
8. Kanai H, et al : Depressed cerebral oxygen metabolism in patients with chronic renal failure : a positron emission tomography study. Am J Kidney Dis 38 : S129-S133, 2001
PubMed
9. Kuwabara Y, et al : Cerebral blood flow and vasodilatory capacity in anemia secondary to chronic renal failure. Kidney Int 61 : 564-569, 2002
PubMed
10. Temple RM, et al : Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. Nephrol Dial Transplant 7 : 240-245, 1992
PubMed
11. Grimm G, et al : Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38 : 480-486, 1990
PubMed
12. 金井秀俊, 他 : 貧血改善の見直し-中枢神経機能. 腎と透析 51 : 179-183, 2001
 
13. Wolfgram DF, et al : Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients. Perit Dial Int 35 : 189-198, 2015
PubMed
14. O'Lone E, et al : Cognition in people with end-stage kidney disease treated with hemodialysis : a systematic review and meta-analysis. Am J Kidney Dis 67 : 925-935, 2015
 
15. Ok E, et al : Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis : a prospective, case-controlled study. Nephrol Dial Transplant 26 : 1287-1296, 2011
PubMed
16. FHN Trial Group : In-center hemodialysis six times per week versus three times per week. N Engl J Med 363 : 2287-2300, 2010
PubMed
17. Fujisaki K, et al : Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice：neuroprotective effect of tempol. Nephrol Dial Transplant 9 : 529-538, 2014
 
18. Haruyama N, et al : Improvement in spatial memory dysfunction by telmisartan through reduction of brain angiotensin II and oxidative stress in experimental uremic mice. Life Sci 113 : 55-59, 2014
PubMed
19. Zhuang S, et al : The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease : A meta-analysis. J Clin Neurosci 33 : 32-38, 2016
PubMed

透析患者の貧血と鉄補充療法

P.84 掲載の参考文献
1. Bailie GR, et al : Variation in intravenous iron use internationally and over time : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 28 : 2570-2579, 2013
PubMed
2. Ferrari P, et al : Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6 (1) : 77-83, 2011
PubMed
3. Hamano T, et al : Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 5 (1) : 23-32, 2015
PubMed
4. Morikami Y, et al : Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial 18 (5) : 414-420, 2014
PubMed
5. Rice L, et al : Neocytolysis on descent from altitude : a newly recognized mechanism for the control of red cell mass. Ann Intern Med 134 (8) : 652-656, 2001
PubMed
6. Brookhart MA, et al : Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24 (7) : 1151-1158, 2013
PubMed
7. Pfeffer MA, et al : TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (21) : 2019-2032, 2009
 
8. Swedberg K, et al : RED-HF Committees ; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 (13) : 1210-1219, 2013
PubMed
9. Loo M, et al : The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 93 (10) : 3286-3293, 1999
PubMed
10. Shovlin CL, et al : Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia : associations with iron deficiency and platelets. PLoS One 9 (2) : e88812, 2014
PubMed
11. Chang YL, et al : Association between ischemic stroke and iron-deficiency anemia : a population-based study. PLoS One 8 (12) : e82952, 2013
PubMed
12. Kulnigg-Dabsch S, et al : Iron deficiency generates secondary thrombocytosis and platelet activation in IBD : the randomized, controlled thrombo VIT trial. Inflamm Bowel Dis 19 (8) : 1609-1616, 2013
 
13. Anker SD, et al : FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (25) : 2436-2448, 2009
PubMed
14. Henry DH, et al : Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 87 (3) : 308-310, 2012
PubMed
15. 秋澤忠男, 他 : 保存期慢性腎臓病患者の腎機能保持 : ESAによる高いヘモグロビン目標値維持の効果. 腎と透析 76 (1) : 119-128, 2014
 
16. Murray-Kolb LE, et al : Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 85 (3) : 778-787, 2007
PubMed
17. David V, et al : Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int : 2017 (in press)
 
18. Yokoyama K, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 (3) : 543-552, 2014
PubMed
19. Prats M, et al : Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients : post-hoc analysis of a prospective study. BMC Nephrol 14 : 167, 2013
 
20. Toblli JE, et al : Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (17) : 1657-1665, 2007
PubMed
21. Ponikowski P, et al : FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function : an analysis of the FAIR-HF study. Eur J Heart Fail 17 (3) : 329-339, 2015
 
22. Ponikowski P, et al : CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 (11) : 657-668, 2015
PubMed
23. Rodby R, et al : Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res 15 (3) : 545-550, 2015
PubMed
24. Agarwal R, et al : A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88 (4) : 905-914, 2015
 
25. Verdon F, et al : Iron supplementation for unexplained fatigue in non-anaemic women : double blind randomised placebo controlled trial. BMJ 326 (7399) : 1124, 2003
PubMed
26. Krayenbuehl PA, et al : Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118 (12) : 3222-3227, 2011
PubMed
27. Sun ER, et al : Iron and restless legs syndrome. Sleep 21 : 371-377, 1998
PubMed
28. Silber MH, et al : Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 78 : 52-54, 2003
PubMed
29. Sloand JA, et al : A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 43 (4) : 663-670, 2004
PubMed

CKD - MBD治療 ( 薬物療法 )

P.89 掲載の参考文献
1. Kidney Disease : Improving Global Outcome (KDIGO) CKD-MBD Work Group. Collaborators : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). Kidney Int (Suppl) 113 : S1-S130, 2009
 
2. Go AS, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (13) : 1296-1305, 2004
PubMed
3. Ohya M, et al : Vascular calcification estimated by aortic calcification area index is significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol 15 : 877-883, 2011
PubMed
4. 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
5. Nakai S, et al : Effect of serum calcium, phosphorus, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12 : 49-54, 2008
PubMed
6. Kestenbaum B, et al : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005
PubMed
7. Bellasi A, et al : Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction. Clin J Am Soc Nephrol 6 : 883-891, 2011
PubMed
8. 日本透析医学会統計調査委員会 : 図説 わが国の慢性透析療法の現況. 2008年12月31日現在
 
9. Hardy P, et al : Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22 : 569-573, 1998
PubMed
10. Masumoto A, et al : Calcium overload accelerates phosphate-induced vascular calcification via Pit-1, but not the calcium-sensing receptor. J Atheroscler Thromb : 2016 (Epub ahead of print)
PubMed
11. Chertow GM, et al : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
PubMed
12. Kakuta T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57 (3) : 422-493, 2012
 
13. Block GA, et al : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 (5) : 438-441, 2007
PubMed
14. Toussaint ND, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis : A pilot randomized controlled trial. Nephrology (carlton) 16 (3) : 290-298, 2011
PubMed
15. Komaba H, et al : Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant 30 (1) : 107-114, 2015
PubMed
16. Shigematsu T, et al : Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreeses serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 27 (3) : 1050-1054, 2012
PubMed
17. Phan O, et al : Effect of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. Biomed Res Int 2015 : 515606, 2015
 
18. Shoji T, et al : Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. Ther Apher Dial 19 (3) : 235-244, 2015
 
19. Hansen D, et al : Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 27 (6) : 2263-2269, 2012
PubMed
20. Ivanovski O, et al : The calcimimetics R-568 retards uremia-enhanced vascular calcification and Atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Athrosclerosis 205 (1) : 55-62, 2009
 
21. Raggi P, et al : ADVANCE Study Group : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 (4) : 1327-1339, 2011
 
22. Sprague SM, et al : Effect of cinacalcet and vitamin analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Nephrol 10 (6) : 1021-1030, 2015
 
23. Cunningham J, et al : Effect of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (4) : 1793-1800, 2005
PubMed

VAIVT ( Vascular Access Intervention Therapy )

P.100 掲載の参考文献
1. 加藤真紀, 他 : 内シャント狭窄に対してアルガトロバンによる抗凝固療法下に経皮的血管形成術 (PTA) を施行し得たヘパリン起因性血小板減少症 (HIT) の1例. 透析会誌 44 (2) : 169-172, 2011
 
2. 星子清貴, 他 : シャントPTA後の止血におけるアルギン酸ナトリウム (アルト) の使用経験. 腎と透析 65 別冊アクセス 2008 : 172-174, 2008
 
3. 中山祐治, 他 : 3 Frシースを使用したVAIVT. 腎と透析 66 別冊アクセス 2009 : 118-120, 2009
 

PD - HD 併用 ( ハイブリット ) 療法

P.108 掲載の参考文献
1. 渡辺修一, 他 : 長期CAPD症例に対するCAPD+HD併用療法についての研究. 透析会誌 26 (Suppl 1) : 911, 1993
 
2. 渡辺修一, 他 : 長期CAPD症例に対するCAPD+HD併用療法の検討. 腎と透析 40 : 129-132, 1996
 
3. Fukui H, et al : Review of combination of peritoneal dialysis and hemodialysis as a modality of treatment for end-stage renal disease. Ther Apher Dial 8 : 56-61, 2004
PubMed
4. 日本透析医学会 : 図説 わが国の慢性透析療法の現況 (2013年12月31日現在) 2014. (http://docs.jsdt.or.jp/overview/index2014.html) 2017.2.20アクセス
 
5. 川西秀樹 : PD+HD併用療法を考えるPD+HD療法の適応と問題点. 透析ケア 7 : 906-911, 2001
 
6. 中山昌明 : 日本透析医学会 2009年版「腹膜透析ガイドライン」. 透析会誌 42 : 285-315, 2009
 
7. Matsuo N, et al : Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis. Clin Nephrol 74 : 209-216, 2010
PubMed
8. Kanno Y,et al : Once-weekly hemodialysis helps continuous ambulatory peritoneal dialysis patients who have insufficient solute removal. Adv Perit Dial 19 : 143-147, 2003
 
9. Kawanishi H, et al : Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int 26 : 150-154, 2006
PubMed
10. Hoshi H, et al : Long-term follow-up of patients treated with a combination of continuous ambulatory peritoneal dialysis and hemodialysis. Adv Perit Dial 22 : 136-140, 2006
PubMed
11. Kawanishi H, et al : Evaluation of dialysis dose during combination therapy with peritoneal dialysis and hemodialysis. Adv Perit Dial 23 : 135-139, 2007
PubMed
12. Tanaka M, et al : Effects of combination therapy with peritoneal dialysis and hemodialysis on left ventricular hypertrophy. Perit Dial Int 31 (5) : 598-600, 2011
PubMed
13. Maruyama Y, et al : Combined therapy with peritoneal dialysis and hemodialysis : a multicenter retrospective observational cohort study in Japan. Blood Purif 38 : 149-153, 2014
PubMed
14. 植田敦志, 他 : 併用 (HD+PD) 導入は残存腎機能と血清アルブミンを保持し, 生命予後を改善させる. 腎と透析 75 別冊 腹膜透析 2013 : 159-160, 2013
 
15. Suzuki H, et al : Early start combination therapy with hemodialysis and peritoneal dialysis prolongs survival and reduces cardiovascular events in male patients. Adv Perit Dial 28 : 68-73, 2012
 

穿刺技術の実際

P.119 掲載の参考文献
1. 日本透析医学会 : わが国の慢性透析療法の現況 2008年12月31日現在. 2009
 
2. 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 2011年版. 透析会誌 44 : 871-885, 2011
 
3. 廣谷紗千子 : AVF-標準的AVF作製. In : 大平整爾 (監) : バスキュラーアクセス治療学, 34, 中外医学社, 東京, 2013
 
4. 石森勇 : 透析患者の穿刺 こうすれば失敗しない (1) 患者側の要因. Clin Eng 27 (5) : 416-422, 2016
 
5. 清水幹夫 : 続・透析患者の穿刺 穿刺者側の要因. Clin Eng 27 (8) : 690-694, 2016
 
6. 若山功治, 他 : バスキュラーアクセス再循環率測定をスクリーニング的に行う必要性. 腎と透析 79 別冊 アクセス 2015 : 145-147, 2015
 
7. 若山功治 : 続・透析患者の穿刺 失敗しないための最終手段 (超音波診断装置の活用). Clin Eng 27 (8) : 695-699, 2016
 

透析関連液の生物学的汚染の測定

P.128 掲載の参考文献
1. 日本透析医学会 : 2016年版 透析液水質基準. 透析会誌 49 (11) : 697-725, 2016
 
2. 楢村友隆, 他 : エンドトキシン測定時におけるサンプリング手技の検討. 腎と透析 65 別冊 HDF療法 '08 : 174-176, 2008
 
3. 川西秀樹, 他 : 新たな透析液水質基準と血液浄化気の機能分類-第49回日本透析医学会コンセンサスカンファレンス「血液浄化器の新分類～内部濾過と透析液水質による再評価」より-. 透析会誌 38 (2) : 149-154, 2005
 
4. 藤原雄太, 他 : エンドトキシン低濃度溶液の測定値に与える保存環境の影響. Clin Eng 22 (10) : 983-990, 2011
 
5. 楢村友隆, 他 : 透析液中の細菌に対する各種メンブレンフィルター法の測定精度の検討. 透析会誌 42 (1) : 85-90, 2009
 
6. 日本臨床工学技士会透析液等安全委員会 : 透析液清浄化ガイドライン Ver. 2.00. 2011
 

最新C型肝炎治療を透析患者にどう適応する ?

P.134 掲載の参考文献
1. 日本透析医学会 (編) : 図説 わが国の慢性透析療法の現況 2007年12月31日現在. 日本透析医学会, 東京, 2008
 
2. Nakai S, et al : Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 14 : 505-540, 2010
PubMed
3. Nakayama E, et al : Prognosis of Anti-HepatitisC Virus Antibody-Positive Patients on Regular Hemodialysis Therapy. J Am Soc Nephrol 11 : 1896-1902, 2000
 
4. 秋葉隆, 他 : 本邦の血液透析施設におけるC型肝炎ウイルス肝炎感染の実態調査. 日透析医会誌 18 (別冊) : 74-82, 2003
 
5. Tanaka J, et al : Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology 51 (1) : 33-41, 2008
 
6. Fissell RB, et al : Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents : The DOPPS. Kidney Int 65 : 2335-2342, 2004
PubMed
7. Iwasa Y, et al : Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol 12 : 53-57, 2008
PubMed
8. 田端秀日朗, 他 : 生体腎移植でのHCV抗体陽性レシピエントにおける腎生着率と生存率の検. 透析会誌 45 (12) : 1147-1153, 2012
 
9. 透析患者のC型ウイルス肝炎治療ガイドライン作成ワーキンググループ : 社団法人日本透析医学会「透析患者のC型ウイルス肝炎治療ガイドライン」. 透析会誌 44 (6) : 481-531, 2011
 
10. Kikuchi K, et al : Multicenter study of pegylated interferon α-2 a monotherapy for hepatitis C virus-infected patients on hemodialysis : REACH study. Ther Apher Dial 18 : 603-611, 2014
 
11. Suda G, et al : Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 51 (7) : 733-740, 2016
PubMed
12. Miyazaki R, et al : Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1 b-Infected Patients on Hemodialysis. Ther Apher Dial 20 (5) : 462-467, 2016
 
13. Toyoda H, et al : Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 51 (7) : 741-747, 2016
PubMed
14. Roth D, et al : Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. Lancet 386 (10003) : 1537-1545, 2015
 

わかりやすい脆弱性骨折対策

P.140 掲載の参考文献
1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy : Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (6) : 785-795, 2001
PubMed
2. Wakasugi M, et al : Increased risk of hip fracture among Japanese hemodialysis patients. Bone Miner Metab 31 (3) : 315-321, 2013
PubMed
3. Moe S, et al : Kidney Disease : Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 (11) : 1945-1953, 2006
PubMed
4. Kazama JJ, et al : Uremic osteoporosis. Kidney Int (Suppl 2011) 3 (5) : 446-450, 2013
PubMed
5. Desmet C, et al : Universite Catholique de Louvain Collaborative Group. Falls in hemodialysis patients : prospective study of incidence, risk factors, and complications. Am J Kidney Dis 45 (1) : 148-153, 2005
 
6. Wang XH, et al : Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 10 (9) : 504-516, 2014
PubMed
7. Kazama JJ : Chronic kidney disease and fragility fracture. Clin Exp Nephrol 21 (Suppl 1) : 46-52, 2017
 
8. Moe SM, et al : Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis : The EVOLVE Trial. J Am Soc Nephrol 26 (6) : 1466-1475, 2015
 
9. Yamamoto S, et al : Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One 10 (4) : e0122691, 2015
PubMed

透析患者に対する運動療法

P.148 掲載の参考文献
1. Silva LC, et al : Knowledge among nephrologists about the importance of exercise in the intradialytic period. J Phys Ther Sci 27 (9) : 2991-2994, 2015
PubMed
2. Young HM : Patient and Staff Perceptions of Intradialytic Exercise before and after Implementation : A Qualitative Study. PLoS One 10 (6) : e0128995, 2015
PubMed
3. Tentori F, et al : Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS) : correlates and associated outcomes. Nephrol Dial Transplant 25 (9) : 3050-3062, 2010
PubMed
4. Matsuzawa R, et al : Relationship between lower extremity muscle strength and all-cause mortality in Japanese patients undergoing dialysis. Phys Ther 94 (7) : 947-956, 2014
PubMed
5. Sheng K, et al : Intradialytic exercise in hemodialysis patients. A systematic review and metaanalysis. Am J Nephrol 40 (5) : 478-490, 2014
PubMed
6. 循環器病の診断と治療に関するガイドライン (2011年度共同研究班報告) : 心血管疾患におけるリハビリテーションに関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2012_nohara_h.pdf (2016.4.20アクセス)
 
7. 前田真治 : リハビリテーション医療における安全管理・推進のためのガイドライン. Jpn J Rehabil Med 44 (7) : 384-390, 2007
Medical*Online
8. National Kidney Foundation : KDOQI Clinical Practice Guideline for Hemodialysis Adequacy. 2015 update. Am J Kidney Dis 66 (5) : 884-930, 2015
PubMed
9. Konstantinidou E : Exercise training in patients with end-stage renal disease on hemodialysis : comparison of three rehabilitation programs. J Rehabil Med 34 (1) : 40-45, 2002
PubMed

カーボカウントによる糖尿病透析患者の食事指導

P.159 掲載の参考文献
1. 日本透析医学会統計調査委員会 : 図説 わが国の慢性透析療法の現況 (2015年12月31日現在). 日本透析医学会, 東京, 2016
 
2. Hyodo T, et al : The Lack of the Knowledge about the Postprandial Blood Glucose by the Education using the Single Absolute Tool for the Diabetic Dietary Therapy in Japan. Arch Renal Dis Manag 1 : 1-2, 2015
 
3. 石田均 : 食品交換表の新たな方向性-日本人での食事療法のエビデンスの確立を目指して-. プラクティス 28 : 485-491, 2011
 
4. 広瀬正和 : 日本人小児1型糖尿病患者におけるカーボカウント法の有用性の検討. 糖尿病 50 : 731-738, 2007
 
5. 三上憲子, 他 : 保存期及び透析期糖尿病性腎症患者に対する基礎および応用カーボカウントの導入. 透析会誌 46 : 691-692, 2013
 
6. The DCCT Research Group : Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. J Am Diet Assoc 93 : 768-772, 1993
 
7. Martha M, et al : #19 Carbohydrate Counting. LIFE with DIABETES. 4 th : American Diabetes Association, 399-424, 2004
 
8. National Kidney Foundation : Carbohydrate counting with chronic kidney disease. http://www.Kidney.org/atoz/content/carbcount.cfm
 
9. 大阪市立大学大学院医学研究科発達小児医学教室, 大阪市立大学医学部附属病院栄養部 (編) : 糖尿病のあなたへ「かんたんカーボカウント～豊かな食生活のために～」. 改訂版, 医薬ジャーナル社, 大阪, 2013
 
10. 厚生労働省「日本人の食事摂取基準 (2015年版) 」策定検討会報告書 : 炭水化物. 菱田明, 佐々木敏 (監修) : 日本人の食事摂取基準 (2015年版), 143-152, 第一出版, 東京, 2014
 
11. 日本糖尿病学会 (編・著) : 糖尿病食事療法のための食品交換表. 第7版, 文光堂, 東京, 2013
 
12. Bantle JP, et al : Nutrition recommendations and interventions for diabetes : a position statement of the American Diabetes Association. Diabetes Care 31 (Suppl 1) : S61-78, 2008
 
13. 日本腎臓学会 (編) : 慢性腎臓病に対する食事療法基準 2014年版. 日腎会誌 56 : 553-559, 2014
 
14. Kitajima Y, et al : Carbohydrate Counting : A Simple Method of Dietary Management for Glycemic Control in Japanese Diabetic Hemodialysis Patients. Contrib Nephrol 189 : 262-269, 2017
PubMed
15. Yamada K, et al : Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 87 : 106-113, 2008
PubMed

書評

最近チェックした商品履歴

Loading...